In addition to the DEGs distinguishing CRPC from both normal prostate and PCa, a two-gene signature was developed based on KIFC2 and BCAS1 in this study, and could be used as a marker for predicting the progression related to castration resistance in PCa patients. This evidence concerns the gene BCAS1 and posterior cortical atrophy.